Study guide
5.2 Enablement Requirement & Wands Factors
USPTO Registration Examination Patent Bar
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview, Registration & MPEP Structure
1.1 Patent Bar Exam Format & Administration 1.2 Practitioner Qualifications & Eligibility 1.3 MPEP Structure & Effective Search Strategies
2 Chapter 2: Subject Matter Eligibility & Utility (35 U.S.C. § 101)
2.1 Patent-Eligible Subject Matter & Statutory Categories 2.2 Judicial Exceptions & the Alice/Mayo Framework 2.3 Utility Requirements & USPTO Utility Guidelines
3 Chapter 3: Novelty & Prior Art Under the AIA (35 U.S.C. § 102)
3.1 First-Inventor-to-File (FITF) & Effective Filing Dates 3.2 The One-Year Inventor Grace Period & Exceptions 3.3 Prior Art Types & Public Availability Standards
4 Chapter 4: Nonobviousness Analysis (35 U.S.C. § 103)
4.1 The Graham Factors & KSR Obviousness Framework 4.2 Combining Prior Art References & Motivation to Combine 4.3 Overcoming § 103 Rejections & Rule 132 Affidavits
5 Chapter 5: Specification & Disclosure Requirements (35 U.S.C. § 112(a))
5.1 Written Description Requirement 5.2 Enablement Requirement & Wands Factors 5.3 Best Mode Requirement & Current Post-AIA Status
6 Chapter 6: Claim Requirements & Definiteness (35 U.S.C. § 112(b)-(f))
6.1 Definiteness & Claim Precision 6.2 Independent & Dependent Claim Construction 6.3 Special Claim Formats: Means-Plus-Function & Markush Claims
7 Chapter 7: Application Types & Filing Procedures (MPEP Chapter 600)
7.1 Provisional Patent Applications 7.2 Nonprovisional Application Parts & Formalities 7.3 Inventor Oaths, Declarations & Assignments
8 Chapter 8: Duty of Disclosure & Information Disclosure Statements
8.1 Duty of Candor & Good Faith 8.2 Information Disclosure Statements (IDS) Requirements 8.3 Correcting Non-Disclosure & Duty Compliance
9 Chapter 9: Patent Prosecution & Office Action Responses (MPEP Chapter 700)
9.1 Initial Examination & Non-Final Office Actions 9.2 Statutory Deadlines & Extension of Time 9.3 Final Office Actions & Post-Final Practice
10 Chapter 10: Continuing Applications & Copendency
10.1 Continuation Applications 10.2 Divisional Applications 10.3 Continuation-in-Part (CIP) Applications & Priority Allocation
11 Chapter 11: Appeals & Interferences/Derivation (MPEP Chapter 1200 & 2300)
11.1 Ex Parte Appeals to the PTAB 11.2 PTAB Appeal Decisions & Judicial Review 11.3 Derivation Proceedings Under the AIA
12 Chapter 12: Post-Grant Proceedings & Corrections (MPEP Chapters 1400 & 2200)
12.1 Reissue Applications & Certificates of Correction 12.2 Ex Parte Reexamination & Supplemental Examination 12.3 Inter Partes Review (IPR) & Post-Grant Review (PGR)
13 Chapter 13: Patent Term, Maintenance Fees & Ownership
13.1 Patent Term Calculation & Patent Term Adjustment (PTA) 13.2 Maintenance Fees & Expiration 13.3 Inventorship, Ownership & Assignment Recordation 13.4 Patent Term Extension Under 35 U.S.C. § 156
14 Chapter 14: International Patent Practice & PCT (MPEP Chapter 1800)
14.1 The Patent Cooperation Treaty (PCT) Overview 14.2 PCT International Phase & Chapter I / Chapter II 14.3 National Phase Entry Under 35 U.S.C. § 371
15 Chapter 15: Special Patent Categories & Professional Conduct
15.1 Design Patents & Plant Patents 15.2 USPTO Rules of Professional Conduct 15.3 Patent Bar Exam Strategy & Open-Book Navigation Tips
16 Chapter 16: Security, Access, Representation & Filing Mechanics
16.1 Secrecy, Application Access & Foreign Filing Licenses 16.2 Representation, Power of Attorney & Correspondence 16.3 Filing Receipt, Certificates of Transmission & Signatures
17 Chapter 17: Restriction, Publication, Allowance & Office Authority
17.1 Restriction, Election, Rejoinder & Double Patenting 17.2 Publication, Preissuance Submissions & Protests 17.3 Allowance, Issue Fee & Withdrawal from Issue 17.4 Examiner Interviews, Petitions & Office Authority
18 Chapter 18: Biotechnology Disclosure & Patent Prosecution Highway
18.1 Biological Deposits & Sequence Listings 18.2 Global/IP5 Patent Prosecution Highway
19 Chapter 19: AIA Trial Practice Under the Consolidated Guide
19.1 AIA Trial Petitions, Preliminary Response & Institution 19.2 AIA Trial Discovery, Motions, Hearing & Final Decision
5.2 Enablement Requirement & Wands Factors
Key Takeaways Explain This Topic AI
35 U.S.C. § 112(a) requires that the specification teach a person ordinarily skilled in the art (POSITA) how to make and use the full scope of the claimed invention without undue experimentation.
In re Wands establishes eight specific factors used by USPTO examiners and courts to evaluate whether required experimentation is undue.
Working examples describe experiments actually performed in past tense, while prophetic or paper examples describe proposed or simulated procedures in present or future tense.
Prophetic examples are legally permissible to satisfy enablement, provided they enable POSITA and do not contain intentionally misleading false statements.
Under MPEP Chapter 2400 and the Budapest Treaty, biological deposits of micro-organisms or cell lines are required when words alone cannot enable POSITA, and must be deposited no later than payment of the issue fee.
Last updated: August 2026
5.2 Enablement Requirement & Wands Factors
Under 35 U.S.C. § 112(a) , the specification must describe the invention in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use the claimed invention.
MPEP § 2164 core standard: The threshold test for enablement is whether the specification discloses sufficient information to enable a person ordinarily skilled in the art (POSITA) to make and use the claimed invention without undue experimentation .
The Undue Experimentation Standard & In re Wands
The law does not prohibit all experimentation. Routine experimentation, standard optimization, or conventional testing to practice the invention is fully permissible. Enablement is violated only when the required experimentation is undue .
In the landmark case In re Wands , 858 F.2d 731 (Fed. Cir. 1988), the Federal Circuit established eight factors (the Wands Factors) that examiners and courts must balance when determining whether experimentation would be undue:
The 8 Wands Factors (MPEP § 2164.01(a))
Quantity of experimentation necessary: The time, effort, and resources required to practice the invention.
Amount of direction or guidance presented: The explicit instructions, protocols, and guidance in the specification.
Presence or absence of working examples: The inclusion of concrete, executed experimental protocols.
Nature of the invention: The technical complexity and scope of the subject matter.
State of the prior art: The level of knowledge, techniques, and public information available to POSITA.
Relative skill of those in the art: The education, training, and experience typical of practitioners in the field.
Predictability or unpredictability of the art: The certainty with which results can be extrapolated.
Breadth of the claims: The scope of coverage sought relative to the specific embodiments disclosed.
Important Supreme Court Note ( Amgen Inc. v. Sanofi , 598 U.S. 594 (2023)): The Supreme Court unanimously reaffirmed the enablement requirement, holding that when claims are drawn to an entire broad class of antibodies defined functionally, the specification must enable the entire class. If making and using the full scope requires POSITA to engage in painstaking trial-and-error discovery across millions of candidate compounds, the claim is invalid for lack of enablement.
Working Examples vs. Prophetic (Paper) Examples
Patent applications frequently contain experimental examples to illustrate how to practice the invention. MPEP § 608.01(p) distinguishes between two types of examples:
Comparison of Example Types
Feature Working Examples Prophetic / Paper Examples
Definition Real experiments actually carried out by inventor Simulated or theoretical experiments not actually run
Grammatical Tense Must be written in Past Tense (e.g., 'was added', 'reacted') Must be written in Present or Future Tense (e.g., 'is added', 'will react')
Legal Status Provides empirical proof of operation Fully valid to satisfy enablement if POSITA could follow them
Duty of Candor False statements constitute inequitable conduct Must NOT be presented as actual tests; misrepresentation violates § 115 / 37 CFR 1.56
Prophetic examples are entirely legitimate in U.S. patent practice. An applicant is not required to build a physical prototype or perform physical laboratory testing before filing a patent application (constructive reduction to practice). However, if prophetic examples are written in the past tense to mislead the examiner into believing real tests were performed, the application risks rejection or invalidation for fraud/inequitable conduct under 37 CFR 1.56 .
Biological Deposit Requirements (MPEP Chapter 2400 & Budapest Treaty)
In certain biological, microbiological, and biotechnological inventions (such as novel hybridomas, specific bacterial strains, or unique cell lines), words and chemical structures alone are insufficient to enable a POSITA to make and use the invention.
To overcome this limitation, the USPTO established biological deposit procedures under 37 CFR 1.801 - 1.809 and MPEP Chapter 2400 , implementing the international Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
Key Rules for Biological Deposits
When Required: A deposit is mandatory if the biological material is essential to practice the invention, is not known and readily available to the public, and cannot be described in writing without undue experimentation.
Approved Depositories: The deposit must be made in an International Depositary Authority (IDA) recognized under the Budapest Treaty (such as the American Type Culture Collection / ATCC).
Timing of Deposit:
The physical deposit must be made on or before the filing date of the application, OR
During pendency, provided the deposit is completed no later than the date of payment of the Issue Fee under 37 CFR 1.804.
Term of Deposit: The deposit must be maintained for at least 30 years from the deposit date AND at least 5 years after the most recent request for a sample, whichever is longer.
Public Access: The depositor must agree that all restrictions on public access to the deposit will be irrevocably removed upon the grant of the patent.